
Website: www.patheon.com
TORONTO, Dec. 13 /CNW/ - Patheon (TSX:PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry, today announced its results for the fourth quarter and year ended October 31, 2006. (All amounts are in U.S. dollars unless otherwise indicated.)
Financial Results
Fourth Quarter Ended October 31, 2006
Compared With Fourth Quarter Ended October 31, 2005
- Revenues declined 4% to $175.1 million;
- EBITDA before repositioning expenses in the fourth quarter was
$19.6 million (11.2% of revenues) compared with $26.2 million
(14.4% of revenues);
- Repositioning expenses, consisting primarily of severance costs
associated with a workforce reduction initiative, were $13.8 million
($12.2 million after tax);
- The provision for income taxes included a reserve of $6.4 million
against the carrying value of future tax assets in the Canadian
operations;
- The net loss was $22.4 million (24.1 cents per share) compared with
net earnings of $8.4 million (9.3 cents per share).
Twelve Months Ended October 31, 2006
Compared With Twelve Months Ended October 31, 2005
- Revenues increased 2% to $712.2 million;
- EBITDA before repositioning expenses was $73.8 million (10.4% of
revenues), compared with $98.0 million (14.0% of revenues);
- Before the asset impairment charge in the third quarter and
repositioning expenses in the fourth quarter of 2006, the loss for
the full year was $23.9 million (25.6 cents per share) vs. net
earnings of $21.6 million (24.9 cents per share);
- The net loss was $288.2 million ($3.10 per share), compared with net
earnings of $21.6 million (24.9 cents per share).
"Fiscal 2006 was an exceptionally difficult year for our Puerto Rico operations and, consequently, for Patheon," said Riccardo Trecroce, Chief Executive Officer, Patheon Inc. "Our Canadian, Cincinnati and European operations achieved growth in both revenues and EBITDA. Our overall earnings, however, were negatively impacted by a series of manufacturing issues and market-driven declines affecting several high-volume products at our Puerto Rico operations."
During the twelve-month period, Patheon's Canadian, Cincinnati and European facilities generated revenues of $582.4 million, up $33.2 million or 6% over fiscal 2005, and EBITDA before repositioning costs of $72.4 million, up $3.9 million or 6%. Full-year revenues at the three Puerto Rico sites, however, declined year-over-year by $19.4 million to $129.8 million, and EBITDA before repositioning costs by $28.1 million to $1.4 million.
"The manufacturing issues in Puerto Rico are being addressed and we saw an improvement in the results of these operations in the fourth quarter relative to the third," Mr. Trecroce said. "With the current operations returning to normal, we will focus on implementing our manufacturing efficiency review process in Puerto Rico to improve the profitability of these operations."
Performance Enhancement Program
"During the fourth quarter, we made significant progress in implementing our previously announced Performance Enhancement Program, which we expect will have a positive impact on our overall earnings in 2007," Mr. Trecroce said.
The Company accelerated its global procurement program, leveraging Patheon's global purchasing power to negotiate contracts which are expected to achieve cost savings in fiscal 2007. These savings are expected to be derived from lower pricing and volume rebates on inventory items, such as excipients and packaging components, as well as non-inventory consumables and services, including laboratory supplies and waste management services.
In addition, Patheon is expanding the manufacturing efficiency review process completed at Whitby Operations to other sites in its network, including the Toronto Region, Cincinnati, Swindon and Carolina facilities. The Whitby project achieved significant gains in production throughput and labour efficiency, contributing towards the site's improved year-over-year earnings performance.
Patheon reduced the size of its global workforce during the fourth quarter by approximately 250 positions, or approximately 4%, to approximately 5,600 full-time equivalent positions as at October 31, 2006. This reduction was implemented to allow the company to move forward into 2007 with a lower cost structure and to adjust for declining business volumes at some sites, particularly at Whitby. Virtually all of the reductions were at the Company's North American facilities, and were achieved through retirements, attrition and terminations with severance packages. This was in addition to the more than 200 positions that were eliminated, mainly through attrition, during the third quarter of fiscal 2006.
Repositioning expenses
The Company recorded $9.6 million in severance expenses in the fourth quarter of 2006 to cover the cost of the workforce reduction plan. In addition, during the fourth quarter, the Company also incurred $4.2 million in consulting and professional fees related principally to work that preceded the decision by the Board to review strategic and financial alternatives for the Company, as well as the expansion of its manufacturing efficiency review process to other sites in its network and the amendment of its North American loan facilities. Total repositioning expenses in the fourth quarter were $13.8 million, ($12.2 million after tax).
Fourth quarter operating results
Although the Company's overall fourth-quarter revenues and EBITDA were lower on a year-over-year basis, EBITDA before repositioning expenses improved over the third quarter, due mainly to improved profitability at the Puerto Rico operations, offset in part by the impact of summer shutdowns in Europe.
Consolidated EBITDA before repositioning expenses of $19.6 million in the fourth quarter represented a decline of $6.6 million or 25% compared with the same period a year ago, but an increase from $16.0 million in the third quarter. The EBITDA margin before repositioning was 11.2% in the fourth quarter, compared with 14.4% a year ago and 8.5% in the third quarter of 2006.
The Puerto Rico commercial manufacturing operations, which had generated a loss in the third quarter, were EBITDA-positive in the fourth quarter, generating EBITDA before repositioning expenses of $0.9 million. This represented a decline of $2.8 million over the same period a year ago, primarily attributable to a year-over-year decline in volumes of Zocor(R), as well as the loss of revenues and earnings from a generic product as a result of the client losing a major account earlier this year. The decline was also partially attributable to a decision taken during the third quarter to temporarily suspend production and shipment of a major product due to stability concerns. Shipments of this product did not resume until September 7, 2006, thereby impacting fourth quarter results.
In Canada, EBITDA before repositioning expenses from commercial manufacturing operations was $6.0 million, or $4.8 million higher than the same period a year ago. The results reflect improved profitability from all operations, in particular from Whitby Operations, which achieved significant improvements in manufacturing efficiencies relative to last year.
In Europe, EBITDA before repositioning expenses from commercial manufacturing operations was $4.2 million, or $6.2 million lower than the same period a year ago. Gains in volumes at Swindon, U.K. and Bourgoin-Jallieu, France were offset by lower capacity utilization at the two sites in Italy. The Italian operations had experienced an exceptionally strong fourth quarter in 2005, attributable to the launch of a new product, as well as a payment received from a client in Europe transferring multiple products to Patheon, for services provided during the 2005 fiscal year relating to the transfer of these products into the Italian facilities.
EBITDA before repositioning expenses from global pharmaceutical development services (PDS) operations was $6.3 million, or $1.5 million lower than the same period in 2005. The PDS operations at Swindon, U.K., Ferentino, Italy and Cincinnati, U.S.A. continued to perform well. The decline reflects lower revenues and profitability in the Puerto Rico and Canadian PDS operations.
Strategic alternatives review process
As previously announced on September 11, 2006, Patheon's Board of Directors has formed a special committee to evaluate a range of strategic and financial alternatives for the Company. As announced on November 16, 2006, the Company is in discussions with a number of parties with regard to various alternatives. As previously announced on October 16, 2006, Patheon negotiated an amendment to its North American credit agreement for the period up to April 30, 2007, establishing amended financial covenants until March 31, 2007. Although the Company is working diligently to implement a long-term improvement to its capital structure before April 30, 2007, there can be no assurance that a transaction or other material development will result from this process prior to that date or at all. No further announcements will be made by the Company with regard to this process unless and until circumstances so warrant.
Outlook
Revenues from the current operations for fiscal 2007 are expected to be comparable to 2006, with decreases in revenues from manufacturing OTC products in Canada offset by increases in revenues from pharmaceutical development services and the manufacture of Rx products in the United States and Europe.
Revenues for the first quarter of 2007 are anticipated to be slightly higher than the same period in fiscal 2006, but less than the fourth quarter of 2006, due in part to seasonal variability of results.
FORWARD-LOOKING STATEMENTS
Cautionary Note
This news release contains forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities.
PLEASE REFER TO THE CAUTIONARY NOTE AT THE END OF THE MANAGEMENT DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ("MD&A") ATTACHED TO AND FORMING PART OF THIS NEWS RELEASE.
WEBCAST CONFERENCE CALL WITH ANALYSTS
Patheon Inc. will host a webcast conference call with financial analysts on its fourth quarter and year end results on Wednesday, December 13, 2006 at 10:00 a.m. (Eastern Standard Time). Representing Patheon on the call will be: Riccardo Trecroce, Chief Executive Officer; Nick DiPietro, President and Chief Operating Officer; and John Bell, Chief Financial Officer. The call will begin with a brief presentation, followed by a question-and-answer period with investment analysts. Interested parties are invited to access the live call, via telephone, in listen-only mode, at (416) 644-3433 (Toronto and International) or toll free at (800) 814-4941 (U.S., including Puerto Rico). Listeners are encouraged to dial in five to 15 minutes in advance to avoid delays. A live audio webcast, with a slide presentation, will also be available via the web at www.patheon.com. An archived version of the Q4 webcast will be available on www.patheon.com for three months.
ABOUT PATHEON
Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,600 people and serving a client base of 200 pharmaceutical and biotechnology companies.
Consolidated Statements of Earnings (Loss)
(unaudited)
Three months ended Twelve months ended
October 31, October 31,
% %
2006 2005 change 2006 2005 change
-------------------------------------------------------------------------
(in thousands of U.S.
dollars, except per
share amounts) $ $ $ $
-------------------------------------------------------------------------
Revenues 175,115 181,893 -3.7% 712,152 698,318 2.0%
Operating expenses 155,550 155,690 -0.1% 638,363 600,356 6.3%
-------------------------- --------------------------
Earnings before
the following: 19,565 26,203 -25.3% 73,789 97,962 -24.7%
-------------------------- --------------------------
(as a % of revenues) 11.2% 14.4% 10.4% 14.0%
Repositioning
expenses (note 8) 13,787 - 13,787 -
Asset impairment
charge (note 3) - - 254,661 -
Depreciation and
amortization 9,944 7,806 27.4% 39,878 33,351 19.6%
Amortization of
intangible assets 2,182 3,443 -36.6% 11,871 11,188 6.1%
Gain on sale of
land (note 9) - (4,587) - (4,587)
Interest 6,247 4,652 34.3% 21,333 16,449 29.7%
Debt prepayment
charges (note 13) - - 1,643 -
Amortization of
deferred financing
costs 346 1,303 -73.4% 944 4,824 -80.4%
Write-off of deferred
financing costs
(note 13) - - 6,332 2,010 215.0%
-------------------------- --------------------------
Earnings (loss)
before income
taxes (12,941) 13,586 -195.3% (276,660) 34,727 -896.7%
Provision for
income taxes 9,475 5,207 82.0% 11,490 13,106 -12.3%
-------------------------- --------------------------
Net earnings (loss)
for the period (22,416) 8,379 -367.5% (288,150) 21,621 -1432.7%
-------------------------- --------------------------
-------------------------- --------------------------
(as a % of revenues) -12.8% 4.6% -40.5% 3.1%
Earnings (loss)
per share
(24.1 9.3 24.9
Basic cents) cents -359.1% ($3.10) cents -1345.0%
-------------------------- --------------------------
(24.1 9.3 24.8
Diluted cents) cents -359.1% ($3.10) cents -1350.0%
-------------------------- --------------------------
Average number of
shares (note 4)
outstanding
during period:
Basic (in
thousands) 92,919 92,846 0.1% 92,868 86,828 7.0%
-------------------------- --------------------------
Diluted (in
thousands) 92,919 93,076 -0.2% 92,868 87,206 6.5%
-------------------------- --------------------------
see accompanying notes
Consolidated Statements of Retained Earnings (Deficit)
(unaudited)
Twelve months ended October 31,
2006 2005
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $
-------------------------------------------------------------------------
Retained earnings, beginning of the year 98,250 76,629
Net earnings (loss) for the period (288,150) 21,621
------------------------
Retained earnings (deficit), end of period (189,900) 98,250
------------------------
------------------------
see accompanying notes
Consolidated Balance Sheets
(unaudited)
(See note 1 - Going Concern Uncertainty) As at As at
October 31, October 31,
2006 2005
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $
-------------------------------------------------------------------------
Assets
Current
Cash and cash equivalents 50,723 22,507
Restricted cash - 7,805
Accounts receivable 121,956 143,646
Inventories 75,962 72,818
Prepaid expenses and other 6,800 4,258
-------------------------
Total current assets 255,441 251,034
-------------------------
Capital assets 494,088 474,793
Intangible assets 41,447 110,095
Deferred costs 9,717 12,342
Future tax assets 21,827 21,368
Goodwill 3,077 180,665
Investment (note 3) 586 1,271
-------------------------
826,183 1,051,568
-------------------------
-------------------------
Liabilities and Shareholders' equity
Current
Bank indebtedness 3,829 14,357
Accounts payable and accrued liabilities 142,781 129,067
Income taxes payable 879 5,650
Current portion of long-term debt (note 12) 283,717 11,360
-------------------------
Total current liabilities 431,206 160,434
-------------------------
Long-term debt (note 12) 62,071 277,181
Other long-term liabilities 25,681 22,755
Deferred revenues 23,366 14,587
Future tax liabilities 33,128 36,760
-------------------------
Total liabilities 575,452 511,717
-------------------------
Shareholders' equity
Share capital 400,721 400,594
Contributed surplus 3,829 2,901
Retained earnings (deficit) (189,900) 98,250
Cumulative translation adjustment 36,081 38,106
-------------------------
Total shareholders' equity 250,731 539,851
-------------------------
826,183 1,051,568
-------------------------
-------------------------
see accompanying notes
Consolidated Statements of Cash Flows
(unaudited)
Three months ended Twelve months ended
October 31, October 31,
2006 2005 2006 2005
-------------------------------------------------------------------------
(in thousands of U.S. dollars) $ $ $ $
-------------------------------------------------------------------------
Operating activities
Net earnings (loss) for
the period (22,416) 8,379 (288,150) 21,621
Add (deduct) charges to
operations not requiring
a current cash payment
Asset impairment charge
(note 3) - - 254,661 -
Depreciation and
amortization 12,472 12,552 52,693 49,363
Write-off of deferred
financing costs (note 13) - - 6,332 2,010
Employee future benefits 434 244 1,564 1,639
Future income taxes (3,514) 1,971 (6,235) 2,642
Gain on sale of land
(note 9) - (4,587) - (4,587)
Amortization of deferred
revenues (485) (280) (1,978) (898)
Other 154 371 1,587 1,745
-----------------------------------------------
(13,355) 18,650 20,474 73,535
Net change in non-cash
working capital balances
related to operations 36,697 5,674 22,142 (4,640)
Increase in deferred
revenues - - 9,614 8,271
-----------------------------------------------
Cash provided by
operating activities 23,342 24,324 52,230 77,166
-----------------------------------------------
Investing activities
Acquisition - 3,343 - (211,823)
Cash acquired on
acquisition - - - 645
-----------------------------------------------
Acquisition net of cash
acquired - 3,343 - (211,178)
Additions to capital assets
- sustaining (7,555) (6,734) (17,804) (16,062)
- project - related (17,800) (11,177) (49,695) (40,730)
Proceeds on sale of land - 4,748 - 4,748
Increase in investments (49) (49)
Increase in deferred
pre-operating costs (625) (703) (2,204) (3,254)
-----------------------------------------------
Cash used in investing
activities (26,029) (10,523) (69,752) (266,476)
-----------------------------------------------
Financing activities
Increase (decrease) in
bank indebtedness 3,041 1,536 (11,096) (6,195)
Increase in long-term debt 42,443 46,355 416,389 341,445
Repayment of long-term
debt (11,790) (55,667) (364,800) (304,838)
Decrease (increase) in
restricted cash - (364) 7,805 (116)
Decrease (increase) in
deferred financing costs (1,175) 3 (3,965) (9,446)
Proceeds on issue of common
shares before costs 47 - 127 199,241
Share issue costs - - - (8,947)
-----------------------------------------------
Cash provided by (used in)
financing activities 32,566 (8,137) 44,460 211,144
-----------------------------------------------
Effect of exchange rate
changes on cash and cash
equivalents 847 494 1,278 (6,953)
-----------------------------------------------
Net increase in cash and
cash equivalents during
the period 30,726 6,158 28,216 14,881
Cash and cash equivalents,
beginning of period 19,997 16,349 22,507 7,626
-----------------------------------------------
Cash and cash equivalents,
end of period 50,723 22,507 50,723 22,507
-----------------------------------------------
-----------------------------------------------
see accompanying notes
Notes to Unaudited Consolidated Financial Statements for the
Year Ended October 31, 2006
(Dollar information in tabular form is expressed in thousands of
U.S. dollars)
1. Accounting policies
Going Concern Uncertainty
The accompanying unaudited consolidated financial statements of Patheon
Inc. (the "Company") have been prepared on a going concern basis, which
contemplates the realization of assets and the discharge of liabilities
in the normal course of business for the foreseeable future. As at
October, 2006 the Company had a working capital deficiency of
$175,765,000. The deficiency includes the reclassification of
$263,842,000 of debt from long term to short term (see note 12). The
Company's ability to continue as a going concern is uncertain and is
dependent upon the successful outcome of the review, announced on
September 11, 2006, of strategic and financial alternatives (see note
15). If the Company is not able to implement a long term improvement in
its capital structure as a result of this review, it anticipates that it
will be in default of the covenants under the North American loan
facilities as at April 30, 2007.
These financial statements do not give effect to any adjustments which
would be necessary should the Company be unable to continue as a going
concern and, therefore, be required to realize its assets and discharge
its liabilities in other than the normal course of business and at
amounts different from those reflected in the accompanying financial
statements.
Basis of Presentation
The accompanying unaudited consolidated financial statements have been
prepared by the Company in accordance with Canadian generally accepted
accounting principles on a basis consistent with those followed in the
most recent audited consolidated financial statements. These consolidated
financial statements do not include all the information and footnotes
required by generally accepted accounting principles for annual financial
statements and therefore should be read in conjunction with the audited
consolidated financial statements and notes included in the Company's
Annual Report for the year ended October 31, 2005.
The preparation of the consolidated financial statements in conformity
with Canadian generally accepted accounting principles requires
management to make estimates and assumptions that affect: the reported
amounts of assets and liabilities; the disclosure of contingent assets
and liabilities at the date of the consolidated financial statements; and
the reported amounts of revenue and expenses in the reporting period.
Management believes that the estimates and assumptions used in preparing
its consolidated financial statements are reasonable and prudent;
however, actual results could differ from those estimates.
In the third quarter of 2006 the Company recorded an impairment charge
against the carrying-value of intangible assets. The company has
re-assessed the estimated economic lives of the assets and is amortizing
the remaining balance on a straight line basis over a period of five
years.
The Company has adopted Accounting Guideline 15 "Consolidation of
Variable Interest Entities". The Guideline requires consolidation of
entities that are deemed to be subject to control on a basis other than
through ownership of a voting interest in the entity. The Company has
concluded that it does not have any variable interest entities and there
is no impact on the financial statements as a result of adopting the
Guideline.
2. MOVA Acquisition
On December 23, 2004, the Company completed the acquisition of MOVA
Pharmaceutical Corporation and MOVA Investments, Inc. (collectively
"MOVA", or the "Puerto Rico operations"), a U.S. prescription
pharmaceutical contract manufacturer located in Puerto Rico, U.S.A.
The acquisition was accounted for using the purchase method and the
accompanying consolidated financial statements include the results of
operations from the date of purchase.
During the second quarter of 2006, MOVA received a notice from the Puerto
Rico Industrial Development Company ("PRIDCO") requesting the accelerated
repayment of a grant that MOVA received in 1996. In accordance with the
terms of the original agreement with PRIDCO, MOVA had been repaying the
grant in the form of royalty payments that are tied to revenues generated
from certain products that MOVA manufactures for its clients. At the time
of the acquisition, escrow funds were set aside as a protection against
PRIDCO exercising a right to an accelerated repayment of the grant, but
these funds were released to the former owners of MOVA at the end of the
escrow period in circumstances where, in retrospect, the Company did not
have a full understanding of PRIDCO's position on whether it would
exercise its right to accelerate repayment of the grant. During the third
quarter of 2006 the Company reached a settlement with the former owners
of MOVA, who have agreed to reimburse MOVA 50% of the amounts owing to
PRIDCO. MOVA's remaining liability is $2,387,000. The Company would have
reflected this liability in the purchase price allocation had it been
aware of it at the time it was finalized. Accordingly, an adjustment has
been made to goodwill, accounts payable and future tax liabilities. The
adjustment to goodwill had the effect of increasing the goodwill
impairment charge (see note 3).
3. Asset Impairment Charge
During the third quarter of 2006 the Company determined that the carrying
value of MOVA's intangible assets, tangible capital assets (collectively
the "long-lived depreciable assets") and goodwill were impaired as a
result of certain events which occurred during the third quarter of 2006.
These events included: continued deterioration in revenues culminating in
a significant increase in losses reported by MOVA in the third quarter;
suspension of production of a major product due to concerns over product
shelf life; the risk of a decline in revenue of another major product as
a result of the approval by the U.S. Food and Drug Administration of a
generic version of the product; and the completion of a long range plan
that showed a significant reduction in earnings relative to prior
forecasts.
The Company tested the recoverability of MOVA's long lived depreciable
assets and determined that expected future cash flows over the economic
life of the principal assets was less than the carrying value of the
long-lived depreciable assets. As a result the Company recorded an
impairment charge of $81,428,000. Based on preliminary analysis, the
impairment charge as at July 31, 2006 was allocated as to $66,249,000 for
intangible assets and $15,179,000 for tangible capital assets. Upon
finalization of the analysis the impairment charge for long lived
depreciable assets has been re-allocated as to $51,921,000 for intangible
assets and $29,507,000 for tangible capital assets. The change in
allocation has no impact on the overall impairment charge. The fair value
of the intangible assets was determined using a discounted cash flow
methodology and the fair value of tangible capital assets was based on a
value in continued use, taking into account utilization levels.
During the third quarter of 2006 the Company also tested the
recoverability of the goodwill associated with MOVA using a discounted
cash flow methodology, and recorded an impairment charge of $172,477,000
representing the full value of the MOVA goodwill.
During the third quarter of 2006 the Company, as part of its ongoing
review of long term investments, concluded that its investment in the
shares of a drug technology company which is accounted for on the cost
basis had an other than temporary decline and wrote down its value by
$756,000 to its market value as of July 31, 2006.
A summary of the asset impairment charges is as follows:
Twelve months ended,
October 31, 2006
--------------------
$
-------------------------------------------------------------------------
MOVA intangible asset impairment 51,921
MOVA tangible capital asset impairment 29,507
MOVA goodwill impairment 172,477
Other investment impairment 756
-------------------------------------------------------------------------
254,661
-------------------------------------------------------------------------
-------------------------------------------------------------------------
4. Average number of shares
The following is a reconciliation of the weighted average number of basic
and diluted shares:
Three months ended October 31,
2006 2005
-------------------------------------------------------------------------
Weighted average number of common
shares outstanding 92,919,384 92,845,688
Effect of dilutive stock options - 230,179
-------------------------------------------------------------------------
Weighted average number of common
shares outstanding - diluted 92,919,384 93,075,867
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Twelve months ended October 31,
2006 2005
-------------------------------------------------------------------------
Weighted average number of common
shares outstanding 92,867,894 86,827,570
Effect of dilutive stock options - 378,029
-------------------------------------------------------------------------
Weighted average number of common
shares outstanding - diluted 92,867,894 87,205,599
-------------------------------------------------------------------------
-------------------------------------------------------------------------
5. Share capital
The following table summarizes information on share capital and related
matters at October 31, 2006:
Outstanding Exercisable
Common shares 92,950,688
Common share stock options 3,949,815 3,617,304
6. Segmented information
The Company is organized and managed as a single business segment, being
the provider of commercial manufacturing and pharmaceutical development
services.
Canadian and foreign operations consist of:
Three months ended Oct 31, 2006
------------------------------------------
Manufacturing Location Canada U.S.A. Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues
Canada 9,201 364 1,337 10,902
USA 41,033 57,719 3,768 102,520
Europe 9,660 339 49,565 59,564
Other geographic areas 500 - 1,629 2,129
-------------------------------------------------------------------------
Total revenues 60,394 58,422 56,299 175,115
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Capital assets 129,725 142,491 221,872 494,088
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Goodwill 3,077 - - 3,077
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Three months ended Oct 31, 2005
------------------------------------------
Manufacturing Location Canada U.S.A. Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues:
Canada 11,339 476 202 12,017
USA 37,487 68,913 2,307 108,707
Europe 8,302 371 51,088 59,761
Other geographic areas 582 103 723 1,408
-------------------------------------------------------------------------
Total revenues 57,710 69,863 54,320 181,893
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Capital assets 122,445 170,334 182,014 474,793
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Goodwill 2,926 177,739 - 180,665
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Twelve months ended Oct 31, 2006
------------------------------------------
Manufacturing Location Canada U.S.A. Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues:
Canada 38,697 856 1,930 41,483
USA 158,706 231,184 13,751 403,641
Europe 53,010 846 202,842 256,698
Other geographic areas 4,696 190 5,444 10,330
-------------------------------------------------------------------------
Total revenues 255,109 233,076 223,967 712,152
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Twelve months ended Oct 31, 2005
------------------------------------------
Manufacturing Location Canada U.S.A. Europe Total
$ $ $ $
-------------------------------------------------------------------------
Revenues:
Canada 32,066 1,294 1,611 34,971
USA 161,645 253,996 9,765 425,406
Europe 39,883 715 190,980 231,578
Other geographic areas 3,548 387 2,428 6,363
-------------------------------------------------------------------------
Total revenues 237,142 256,392 204,784 698,318
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Revenues are attributed to countries based on the location of the
client's billing address, capital assets are attributed to the country in
which they are located, and goodwill is attributed to the country in
which the entity to which the goodwill pertains is located.
Revenue information by service activity is as follows:
Three months ended Oct 31,
------------------------------------------
2006 2005
$ $
-------------------------------------------------------------------------
Commercial manufacturing
- prescription 126,117 72% 127,696 70%
Commercial manufacturing
- over-the-counter 20,211 12% 27,675 15%
Development services 28,787 16% 26,522 15%
-------------------------------------------------------------------------
175,115 100% 181,893 100%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Twelve months ended Oct 31,
------------------------------------------
2006 2005
$ $
-------------------------------------------------------------------------
Commercial manufacturing
- prescription 508,233 71% 498,113 71%
Commercial manufacturing
- over-the-counter 104,908 15% 109,153 16%
Development services 99,011 14% 91,052 13%
-------------------------------------------------------------------------
712,152 100% 698,318 100%
-------------------------------------------------------------------------
-------------------------------------------------------------------------
7. Stock-based compensation
The Company has an incentive stock option plan. Persons eligible to
participate in the plan are directors, officers, and key employees of the
Company and its subsidiaries or any other person engaged to provide
ongoing management or consulting services to Patheon. The plan provides
that the maximum number of shares that may be issued under the plan is
7.5% of the issued and outstanding common shares of the Company at any
point in time. As of October 31, 2006, the total number of common shares
listed and reserved at the TSX for issuance under the plan was 6,858,427,
of which there are stock options outstanding to purchase 3,949,815 shares
under the plan. The exercise price of common shares subject to an option
is determined at the time of grant and the price cannot be less than the
weighted average market price of the common shares of Patheon on the
Toronto Stock Exchange during the two trading days immediately preceding
the grant date. Options generally expire 10 years after the grant date
and are also subject to early expiry in the event of death, resignation,
dismissal or retirement of an optionee. Options generally vest over three
years, one-third on each of the first, second and third anniversary of
the grant date.
The fair value of stock options is estimated at the date of the grant.
There were no options granted for the three months ended October 31,
2006. (The weighted average fair value for the stock options granted for
the three months ended October 31, 2005 was $3.04). The weighted average
fair value of stock options granted for the twelve months ended
October 31, 2006 was $1.73 (2005-$3.01). The fair value of stock options
is estimated at the date of grant using the Black-Scholes option pricing
model. The following assumptions were used in arriving at the fair value
of options issued during the twelve months ended October 31, 2006:
Risk free interest rate 4.2%
Expected volatility 42%
Expected weighted average life of options 4 years
Expected dividend yield 0%
Stock-based compensation expense recorded in the three months ended
October 31, 2006 was $3,000 (2005 - $319,000) for options granted on or
after November 1, 2003. Stock based compensation expense recorded for the
twelve months ended October 31, 2006 was $928,000 (2005-$1,528,000) for
options granted on or after November 1, 2003.
Stock options granted prior to November 1, 2003 are accounted for using
the intrinsic value method, which does not give rise to compensation
expense. Had these stock options been accounted for at fair value, the
pro-forma net earnings (loss) and earnings (loss) per share would have
been:
(in thousands of U.S. Three months ended Twelve months ended
dollars) October 31, October 31,
2006 2005 2006 2005
-------------------------------------------------------------------------
$ $ $ $
-------------------------------------------------------------------------
Net earnings (loss) as
reported (22,416) 8,379 (288,150) 21,621
Pro-forma adjustments for
the fair value of stock
options granted prior to
November 1, 2003 - 27 (28) (98)
-------------------------------------------------------------------------
Pro-forma net earnings
(loss) (22,416) 8,406 (288,178) 21,523
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Pro-forma earnings
(loss) per share:
Basic (24.1 9.3 ($3.10) 24.8
cents) cents cents
Diluted (24.1 9.3 ($3.10) 24.7
cents) cents cents
8. Repositioning expenses
During the fourth quarter of 2006 the Company incurred a number of
expenses associated with its performance enhancement program, which is
intended to identify operational improvements and cost reduction
initiatives. The related expenses include costs associated with a
reduction in the work force and consulting fees from external specialists
who are assisting in identifying operational improvements.
During the fourth quarter of 2006 the Company also incurred professional
fees, in connection with the amendment to its North American Loan
Facilities (see note 12) and its review of strategic and financial
alternatives (see note 15).
The following is a summary of expenses associated with these initiatives
(collectively "Repositioning Expenses"):
Three months and
Twelve months ended
October 31, 2006
----------------------
$
-------------------------------------------------------------------------
Performance enhancement program:
- Employee-related expenses 9,610
- Consulting and professional fees 1,193
Loan amendments and strategic alternatives review 2,984
-------------------------------------------------------------------------
13,787
-------------------------------------------------------------------------
-------------------------------------------------------------------------
As at October 31, 2006 $9,487,000 of the Repositioning Expenses are
unpaid and are recorded in accounts payable and accrued liabilities.
9. Gain on sale of land
During the fourth quarter 2005, the Company disposed of a parcel of land
at its Bourgoin-Jallieu site in France. The sale closed October 17, 2005.
The proceeds received on the sale were $4,748,000 and the gain attributed
on the sale was $4,587,000.
10. Other information
Foreign exchange
During the three months ended October 31, 2006, the foreign exchange gain
was $987,000 (2005 loss - $141,000). For the twelve months ended
October 31, 2006, the foreign exchange gain was $1,065,000 (2005 gain -
$2,603,000).
Employee future benefits
The employee future benefit expense in connection with defined benefit
pension plans and other post retirement benefit plans for the three
months ended October 31, 2006 was $1,671,000 (2005 - $1,366,000). For the
twelve months ended October 31, 2006, the employee future benefit expense
was $5,416,000 (2005 - $5,463,000).
11. Financial instruments
The Company utilizes financial instruments to manage the risk associated
with fluctuations in foreign exchange rates and interest rates. The
Company formally documents all relationships between hedging instruments
and hedged items, as well as its risk management objective and strategy
for undertaking various hedge transactions.
The Company has entered into foreign exchange forward contracts with an
aggregate amount of US$60,000,000 as at October 31, 2006. These contracts
mature at the latest on October 29, 2007 at exchange rates varying
between $1.0856 and $1.096 Canadian. The mark-to-market value on these
financial instruments as at October 31, 2006 was an unrealized loss of
US$1,418,000.
In the second quarter of 2006, the Company unwound its interest rate swap
contracts that exchanged a notional amount of US$107,500,000 of debt from
floating to fixed interest rates. The gain of $1,097,000 that was
realized on the unwinding of the swaps is being amortized to interest
expense over approximately six years, reflecting the maturity dates of
the original contracts.
As at October 31, 2006 the Company has designated $200 million of
US dollar denominated debt as a hedge against its equity investment in
its operations in the U.S.A. and Puerto Rico. The exchange gains and
losses arising from this debt accumulate in the cumulative translation
adjustment account in shareholders' equity.
12. Long-term debt
On December 15, 2005, the Company completed the negotiation of new credit
facilities in North America (the "North American Loan Facilities") in the
aggregate amount of $290,000,000 to refinance existing debt of the
Company and its U.S. subsidiaries including its subsidiaries in Puerto
Rico. The new facilities replaced (i) existing credit facilities that
were available to the Company's North American operations including those
that were established at the time of acquisition of MOVA in December
2004, and (ii) debt of MOVA that was assumed at the time of acquisition
by the Company. The new credit facilities comprise two term loans in the
aggregate amount of $215,000,000 and three year revolving facilities in
an aggregate amount of $75,000,000. The term loans consist of a five-year
term loan of $50,000,000 and a six-year term loan of $165,000,000. The
new credit facilities bear interest at floating rates based on bankers'
acceptances, Canadian and U.S. prime, U.S. base rate, or U.S. LIBOR, plus
spreads between 0.75% and 2.5%. The new facilities are collateralized by
the North American assets of Patheon and its subsidiaries, including
those of Puerto Rico.
During the third quarter of 2006, certain of the financial covenant tests
included in the North American Loan Facilities were amended to ensure
that the Company remained in compliance as at July 31, 2006. During the
fourth quarter of 2006, the Company entered into a further agreement with
its lenders to amend the North American Loan Facilities. The agreement
reduced the amount of the revolving credit facilities from $75,000,000 to
$60,000,000 and established amended financial covenants, including
trailing 12-month debt-to-EBITDA covenants. The amended covenants cover a
six-month period ending on March 31, 2007.
If the Company is not able to implement a long term improvement in its
capital structure as a result of its review of strategic and financial
alternatives (see note 15), it anticipates that it will be in default of
the covenants under the North American Loan Facilities as at April 30,
2007 and the lenders could demand repayment of all amounts outstanding
under these credit facilities. Accordingly, in accordance with Emerging
Issues Committee Abstract 59, the Company has re-classified $239,952,000
of debt from long-term to short-term, representing the long-term portion
of debt outstanding under the North American Loan Facilities. Any future
default under the Company's North American Loan Facilities would cause a
cross default under a lending facility in its UK subsidiary. Accordingly,
the Company has also reclassified $23,890,000 of related debt from long-
term to short-term.
On December 22, 2005, the Company's Italian subsidiary entered into a new
long-term debt facility. The new loan replaced four separate term loans
it had with an Italian bank. The new loan in the amount of (euro)
28,500,000 ($33,856,000), bearing interest at floating rates based on
3-month Euribor maturing in 2014, has equal semi-annual principal
payments over the term of the nine year loan, and is collateralized by a
mortgage over land and buildings.
13. Debt prepayment charges and write-off of deferred financing costs
During the first quarter of 2006, the Company incurred charges of
$1,643,000 in connection with the cancellation and prepayment of certain
of its North American credit facilities. The Company also wrote off
$6,332,000 in related deferred financing costs in the first quarter of
2006.
During the first quarter of 2005, the Company wrote off deferred
financing costs of $2.0 million associated with commitment fees paid for
financing that was not required in connection with the MOVA acquisition.
14. Related Party Transactions
Revenues and recharges for cost recoveries from companies controlled by a
director and significant shareholder of the Company were in the amount of
$260,000 and $3,145,000 for the three and twelve months ended October 31,
2006 respectively. These transactions were conducted in the normal course
of business and are recorded at the exchanged amount which management
believes to be at fair value. Accounts receivables at October 31, 2006
include a balance of $446,000 resulting from these transactions.
At October 31, 2006 the Company has an investment of $173,000,
representing an 18% interest in two Italian companies whose largest
investor is an officer of the Company. These newly formed companies will
specialize in the manufacturing of cytotoxic pharmaceutical products.
15. Review of Strategic and Financial Alternatives
On September 11, 2006 the Company announced that its Board of Directors
had established a special committee to evaluate a range of strategic and
financial alternatives for the Company. Financial advisors were also
appointed to assist the special committee and the Company in this
process. The Company is in discussions with a number of parties with
regard to various alternatives. There can be no assurance that a
transaction or other material development will result from this process.
16. Comparative amounts
Certain other comparative amounts have been reclassified to conform to
the current period presentation.
Patheon Inc.
Management's Discussion and Analysis of Financial Condition and
Results of Operations
The following management discussion and analysis of financial condition
and results of operations ("MD&A") of Patheon Inc. ("Patheon" or "the
Company") for the three-month and twelve-month periods ended October 31, 2006
and 2005 should be read in conjunction with the Company's consolidated
financial statements and related notes contained in this interim report. This
MD&A is dated as of December 13, 2006.
The purpose of this 2006 fourth quarter report is to provide an update to
the information contained in the Management's Discussion and Analysis section
of the Company's 2005 Annual Report, which contains a more comprehensive
discussion of Company's strategy, capabilities to deliver results, risks and
key performance indicators. Management assumes that the reader of this
document has access to the MD&A section of the Company's 2005 Annual Report.
This document and other information can be downloaded in portable document
format (PDF) from the Company's web site at www.patheon.com or from the SEDAR
web site for Canadian regulatory filings at www.sedar.com. To request a
printed copy, the reader may also contact Patheon's transfer agent,
Computershare Trust Company of Canada, at 1-800-564-6253 or via email at
service@computershare.com, or Patheon at www.patheon.com.
Use of Non-GAAP Financial Measures
Except as otherwise indicated, references in this MD&A to "EBITDA before
repositioning expenses" are to earnings before repositioning expenses, asset
impairment charges, depreciation and amortization, gain on sale of land,
interest, debt prepayment charges, write-off of deferred financing costs, and
income taxes. "EBITDA margin before repositioning expenses" is EBITDA before
repositioning expenses divided by revenues. EBITDA before repositioning
expenses and EBITDA margin before repositioning expenses are measures of
earnings or earnings margin not recognized by generally accepted accounting
principles in Canada ("Canadian GAAP"). Since each of these measures is a
non-GAAP measure that does not have a standardized meaning, it may not be
comparable to similar measures presented by other issuers. Prospective
investors are cautioned that these, and other non-GAAP measures should not be
construed as alternatives to net earnings determined in accordance with
Canadian GAAP as indicators of performance. The Company has included these
measures because it believes that this information is used by certain
investors to assess financial performance.
Overview of Patheon
Patheon is focused exclusively on providing commercial manufacturing and
pharmaceutical development services to pharmaceutical, biotechnology and
specialty pharmaceutical companies located primarily in North America, Europe
and Japan. Patheon serves its international clientele from its operating
facilities in North America (including Puerto Rico) and Europe.
Patheon commercially manufactures prescription ("Rx") and over-the-
counter ("OTC") products in solid, semi-solid and liquid dosage forms and
manufactures Rx products in various sterile dosage forms. Conventional dosage
forms include compressed tablets, hard-shell capsules, powders, ointments,
creams, gels, syrups, suspensions, solutions and suppositories. Sterile dosage
forms include liquids filled in ampoules, vials, bottles or pre-filled
syringes. Sterile lyophilized products are also manufactured in both vials and
ampoules.
Patheon provides manufacturing services for a broad range of products in
many dosage forms and packaging formats in accordance with client
specifications. Depending on the particular client, Patheon may be responsible
for most or all aspects of the manufacturing and packaging process, from
sourcing excipient raw materials and packaging components to delivering the
finished product in consumer-ready form to the client. Typically, Patheon's
clients supply the active pharmaceutical ingredients ("API") used in the
production process.
The pharmaceutical development services provided by Patheon include most
of the pharmaceutical development services typically required by companies
conducting clinical trials and preparing for full-scale commercial production
of a new drug.
At October 31, 2006, there were a total of 171 client products in the
Patheon's pharmaceutical development services ("PDS") pipeline, including five
drug candidates at the New Drug Application ("NDA") stage. This compares with
a total of 147 client products a year ago. During the fourth quarter, two
products being developed on behalf of clients received regulatory approval and
were launched from the Company's facilities.
Vision and Strategy
Patheon's vision is to be the leader in pharmaceutical manufacturing.
Patheon strives to be the preferred manufacturing and pharmaceutical
development services partner to the global pharmaceutical industry. Patheon's
strategy is to offer strategic benefits to its clients by providing
comprehensive, high-quality and integrated manufacturing services throughout
the product lifecycle.
Patheon expects that stronger manufacturing and development relationships
will continue to emerge between pharmaceutical companies and service companies
as the pharmaceutical industry continues to re-evaluate its internal
manufacturing capabilities and streamlines its external service-provider
network. The Company is using its position as a comprehensive provider of
commercial manufacturing services to establish and maintain long-term and
strategic relationships with clients on a global basis.
The development of Patheon's business in recent years has been guided by
a plan to expand capacity, expertise and capabilities, positioning the Company
to be the preferred manufacturing services partner to the pharmaceutical
industry. This has led to the acquisition of several pharmaceutical
manufacturing facilities and the entry into long-term manufacturing
relationships in conjunction with certain of these acquisitions. In addition
to this strategic growth, Patheon is focused on growing the business
internally, by expanding the level of business from existing clients,
attracting new clients and entering into commercial manufacturing agreements
for newly approved products for which the Company has provided development
services.
In implementing its strategy, the Company will continue to maximize
capacity utilization and improve efficiency, broaden its services to include
other manufacturing capabilities and seek to increase the percentage of more
profitable products manufactured at its facilities. In addition, the Company
will seek to expand its PDS capabilities in North America and Europe to better
serve the needs of the global pharmaceutical industry. Pharmaceutical
development services are an important source of new business for commercial
manufacturing of prescription pharmaceuticals.
Key Performance Drivers
In Patheon's 2005 Annual Report, several key performance drivers were
identified for the Company: (i) increasing the percentage of more profitable
Rx products at its facilities; (ii) expanding its PDS capabilities in North
America and Europe; (iii) improving capacity utilization at the Company's
sites, which have a largely fixed-cost base in the short term; and (iv)
mitigating the impact of changes in the foreign exchange trading relationship
between the Canadian and U.S. dollar, since the Company's contracts in North
America are primarily denominated in U.S. dollars, but the operating expenses
of its six Canadian sites are primarily denominated in Canadian dollars. At
the end of the second quarter of 2006 the Company also initiated a performance
enhancement program aimed at improving the productivity and cost effectiveness
of its operations. An update on our interim performance relating to these key
measures is provided in the section below entitled "Results of Operations."
Recent Developments
Financing Arrangements and Strategic Alternatives
In anticipation of lower-than-expected earnings and EBITDA for the third
quarter ended July 31, 2006, in July 2006 the Company commenced negotiations
with its lenders in respect of amendments to certain financial covenants under
its North American loan facilities because of concern that, based on its
latest internal forecast at that time, the Company would not be in compliance
with its debt-to-EBITDA ratio and fixed charge coverage financial covenants as
at July 31, 2006. As a result of the amendments, the Company was in compliance
with the terms and conditions of its North American loan facilities as at
July 31, 2006. During the fourth quarter of 2006, the Company entered into a
further agreement with its lenders to amend the North American loan
facilities. The agreement reduced the amount of the revolving credit
facilities from $75,000,000 to $60,000,000 and established amended financial
covenants, including trailing 12-month debt-to-EBITDA covenants. The amended
covenants cover a six-month period ending on March 31, 2007.
On September 11, 2006, the Company announced that its Board of Directors
had formed a special committee to evaluate a range of strategic and financial
alternatives for the company. Greenhill & Co. and RBC Capital Markets have
been retained as financial advisors to assist the Company and the special
committee.
If the review of strategic and financial alternatives does not result in
an improvement in the Company's capital structure, the Company anticipates
that it will be in default under its North American loan facilities as at
April 30, 2007 and the lenders could demand repayment of all amounts
outstanding under these credit facilities. As at November 30, 2006,
$237.9 million was outstanding under these facilities ($246.0 million as at
October 31, 2006). In addition, any such default would constitute a default
under a lending facility of the company's U.K. subsidiary, allowing the lender
under this facility to immediately demand repayment of all amounts outstanding
under that facility. As at November 30, 2006, $24.6 million was outstanding
under that facility ($23.9 million as at October 31, 2006).
The Company is able to borrow under its amended $60 million North
American revolving loan facility. As at November 30, 2006, $35.3 million was
borrowed under this facility ($36.9 million as at October 31, 2006). The
maximum amount that may be borrowed under this facility from time-to-time is a
function of borrowing base calculations prescribed in the credit agreement,
and is typically less than $60 million. The Company estimates that, based on
these borrowing base calculations, as at November 30, 2006, an additional
$17.9 million was available to be drawn under this facility. In addition the
Company has cash reserves on hand of approximately $45.1 million at
November 30, 2006 ($50.7 million as at October 31, 2006). The Company is
satisfied that it has sufficient liquidity to carry on its business in the
ordinary course for the period covered by the amendment to the North American
loan facilities.
Going Concern Uncertainty Note
As at October 31, 2006, the Company has reclassified the long-term debt
outstanding under its North American loan facilities ($240.0 million) and its
U.K. subsidiary's loan facility ($23.9 million) as current indebtedness, in
accordance with Emerging Issues Committee Abstract 59, which requires such
reclassification unless a violation of the covenants under these credit
facilities at a future compliance date within one year of the balance sheet
date is not likely. See "Liquidity and Capital Resources - Adequacy of
Financial Resources" and "Critical Accounting Policies and Estimates - Going
Concern Uncertainty", below. As a result of this reclassification, the Company
had a working capital deficiency as at October 31, 2006 of $175.8 million.
Consequently, the Company's consolidated financial statements for the fourth
quarter include a going concern uncertainty note, stating that the Company's
ability to continue as a going concern is uncertain and is dependent upon the
successful outcome of the review of strategic and financial alternatives
announced September 11, 2006. The Company's consolidated financial statements
as at and for the fourth quarter ended October 31, 2006 do not give effect to
any adjustments which would be necessary should the Company be unable to
continue as a going concern.
Developments relating to MOVA
On December 23, 2004, the Company completed the acquisition of MOVA
Pharmaceutical Corporation and MOVA Investments, Inc. (collectively "MOVA", or
the "Puerto Rico operations"), a U.S. prescription pharmaceutical contract
manufacturer located in Puerto Rico, U.S.A.
The acquisition was accounted for using the purchase method and the
accompanying consolidated financial statements include the results of
operations from the date of purchase.
During the second quarter of 2006, MOVA received a notice from the Puerto
Rico Industrial Development Company ("PRIDCO") requesting the accelerated
repayment of a grant that MOVA received in 1996. In accordance with the terms
of the original agreement with PRIDCO, MOVA had been repaying the grant in the
form of royalty payments that are tied to revenues generated from certain
products that MOVA manufactures for its clients. At the time of the
acquisition, escrow funds were set aside as a protection against PRIDCO
exercising a right to an accelerated repayment of the grant, but these funds
were released to the former owners of MOVA at the end of the escrow period in
circumstances where, in retrospect, the Company did not have a full
understanding of PRIDCO's position on whether it would exercise its right to
accelerate repayment of the grant. The potential repayment obligation was
noted as a contingent liability in the Company's second quarter financial
statements pending investigation of whether the accelerated repayment of the
grant was the responsibility of the former owners of MOVA. During the third
quarter of 2006 the Company reached a settlement with the former owners, who
have agreed to reimburse MOVA 50% of the amounts owing to PRIDCO. MOVA's
remaining liability is $2.4 million. The Company would have reflected this
liability in the purchase price allocation had it been aware of it at the time
it was finalized, accordingly an adjustment has been made to goodwill,
accounts payable and future tax liabilities. The adjustment to goodwill had
the effect of increasing the goodwill impairment charge.
During the third quarter of 2006, the Company determined that the
carrying value of MOVA's intangible assets, tangible capital assets and
goodwill were impaired. Accordingly, the Company recognized an aggregate asset
impairment charge of $253.9 million in respect of these assets for the quarter
($51.9 million in respect of intangible assets; $29.5 million in respect of
tangible capital assets; and $172.5 million in respect of goodwill). See
"Results of Operations - Asset Impairment Charge", below.
Results of Operations
Three Months Ended October 31, 2006 Compared with Three Months Ended
October 31, 2005
Revenues by Geographic Region and Service Activity
Three months ended Twelve months ended
Oct 31, Oct 31,
2006 2005 % 2006 2005 %
Change Change
--------------------------------------------------
North America
-------------
Commercial
Manufacturing
Prescription 78,909 78,885 0% 310,880 313,078 -1%
Over-the-counter 19,041 27,420 -31% 101,262 107,337 -6%
--------------------------------------------------
97,950 106,305 -8% 412,142 420,415 -2%
Development Services 20,866 21,268 -2% 76,043 73,119 4%
--------------------------------------------------
118,816 127,573 -7% 488,185 493,534 -1%
--------------------------------------------------
Europe
------
Commercial
Manufacturing
Prescription 47,208 48,811 -3% 197,353 185,035 7%
Over-the-counter 1,170 255 359% 3,646 1,816 101%
--------------------------------------------------
48,378 49,066 -1% 200,999 186,851 8%
Development Services 7,921 5,254 51% 22,968 17,933 28%
--------------------------------------------------
56,299 54,320 4% 223,967 204,784 9%
--------------------------------------------------
TOTAL
-----
Commercial
Manufacturing
Prescription 126,117 127,696 -1% 508,233 498,113 2%
Over-the-counter 20,211 27,675 -27% 104,908 109,153 -4%
--------------------------------------------------
146,328 155,371 -6% 613,141 607,266 1%
Development Services 28,787 26,522 9% 99,011 91,052 9%
--------------------------------------------------
CONSOLIDATED REVENUES 175,115 181,893 -4% 712,152 698,318 2%
--------------------------------------------------
--------------------------------------------------
Revenues
Consolidated revenues for the three-month period ended October 31, 2006
decreased 4%, or $6.8 million, to $175.1 million from $181.9 million in the
same period in 2005. In the fourth quarter, revenue declines in both Rx and
OTC manufacturing were offset in part by growth in revenues from PDS. On a
consolidated basis, Rx manufacturing revenues declined by 1% and OTC revenues
declined by 27% compared with the fourth quarter of 2005. PDS revenues
increased 9% over the same period in 2005.
Prescription manufacturing and development services represented 88% of
revenues, compared with 85% for the comparable period in 2005.
Geographically, in North America, revenues declined in the fourth quarter
by $8.8 million or 7% over the same period a year ago. Revenues from the
Puerto Rico operations were $33.9 million, down from $40.9 million, or 17%, in
the same period a year ago, but up $5.9 million relative to the third quarter
of 2006. The year-over-year decline was primarily attributable to the loss,
earlier this year, of revenues from a generic product where the Company's
client lost a major customer and the loss in patent protection of Zocor(R).
This was offset in part by higher volumes from the Carolina facility, which in
2005 was impacted by a temporary shut down in production in response to an FDA
warning letter. The improvement relative to the third quarter of 2006 reflects
the resumption of shipping of a high volume product in Caguas that had been
affected by stability-related issues during the third quarter, along with
higher volumes from the Carolina facility to meet client demands for
cephalosporin products for the cough and cold season.
Revenues from the other operations in North America were $84.9 million,
or 2% lower than the same period last year. The net decline reflects a
$6.3 million, or 16%, increase in Rx revenues, offset by a $8.4 million, or
31%, decline in OTC revenues. Rx revenues were higher in the Canadian
operations offset by a small decline in Cincinnati. OTC revenues declined in
the Canadian operations and in Cincinnati as the Company continues to be
impacted by price competition in the OTC market. Revenues from PDS services
increased $0.3 million or 2% over the same period a year ago, with continuing
growth in Cincinnati being offset by declines in late stage project revenues
in Canada.
In Europe, revenues for the fourth quarter of 2006 were $2.0 million or
4% higher than the same period of 2005. The year-over-year increase in
revenues reflects a $2.7 million, or 51% increase in PDS revenues from the
Swindon, U.K. and Ferentino, Italy operations, offset by a $0.7 million, or 1%
reduction in commercial revenues. The change in commercial revenues reflects
year-over-year improvements in Swindon, U.K. and Bourgoin Jallieu, France,
offset by a decline from the Italian operations. European currencies
strengthened against the U.S. dollar in the fourth quarter of fiscal 2006
compared with the prior year. The Euro strengthened approximately 4% and U.K.
sterling strengthened approximately 5% against the U.S. dollar, increasing
reported revenues by approximately $2.5 million. Had European currencies
remained constant to the rates of the prior year, European revenues would have
been 1% lower than the same period in 2005.
Operating Expenses
Operating expenses comprise processing costs (principally materials,
employee and other site-related costs), marketing, sales, service, corporate
support and administrative expenses. In the fourth quarter of 2006, operating
expenses were $155.6 million, being $0.1 million lower than the same period a
year ago. Operating expenses were impacted by lower volumes, savings from the
performance enhancement program, and lower bonus costs, offset by annual
payroll-related increases and the impact of the strengthening Canadian dollar
and European currencies relative to the U.S. dollar. Operating expenses as a
percentage of revenues were 88.8%, compared with 85.6% in the same period a
year ago.
Repositioning Expenses
During the fourth quarter of 2006 the Company incurred $13.8 million of
expenses in connection with its performance enhancement program, amendments to
its North American bank financing facilities and its review of strategic and
financial alternatives. The expenses include costs associated with a reduction
in the work force and consulting and professional fees. The Company expects to
incur further repositioning expenses in its 2007 fiscal year as it completes
the performance enhancement program and review of strategic and financial
alternatives.
EBITDA before repositioning expenses and EBITDA margin before
repositioning expenses
On a consolidated basis in the fourth quarter of 2006, EBITDA before
repositioning expenses, representing earnings before repositioning expenses,
asset impairment charges, depreciation and amortization, gain on sale of land,
interest, debt prepayment charges, write-off of deferred financing costs, and
income taxes was $19.6 million, compared with $26.2 million in the same period
a year ago. EBITDA margin before repositioning expenses was 11.2% in the
three-month period, compared with 14.4% in the same period a year ago.
The profitability of Canadian operations was impacted by the
strengthening of the Canadian dollar relative to the U.S. dollar. The Canadian
dollar strengthened by approximately 6% relative to the U.S. dollar, compared
with the fourth quarter of 2005. The Company estimates that, had exchange
rates remained the same as last year, its EBITDA before repositioning
expenses, net of hedging activities, would have been approximately
$0.8 million higher than was reported.
EBITDA before repositioning expenses from the Puerto Rico commercial
operations was $0.9 million, being $2.8 million lower than the same period
last year. The decrease reflects significantly lower capacity utilization in
the Caguas facility offset in part by higher utilization in the Carolina
facility, which in the prior year was impacted by a temporary shut down in
production of a certain product in response to an FDA warning letter last
year. The Caguas operations were also impacted by a decision taken during the
third quarter to temporarily suspend production and shipment of a major
product due to stability concerns. Shipments of this product resumed on
September 7, 2006.
In the Cincinnati commercial operations, EBITDA before repositioning
expenses was $4.7 million, being $1.3 million lower than the same period last
year. The decline principally reflects the impact of lower OTC volumes.
In Canada, EBITDA before repositioning expenses from the commercial
operations was $6.0 million, being $4.8 million higher than the same period
last year. The improvement reflects improved profitability from all
operations, in particular from Whitby operations, which in fourth quarter of
2005 was impacted by a number of manufacturing inefficiencies that were
resolved during the second and third quarters of 2006.
In Europe, EBITDA before repositioning expenses from the commercial
manufacturing operations was $4.2 million, being $6.2 million lower than same
period a year ago. The decline principally reflects lower capacity utilization
in the Italian operations, relative to the exceptionally strong fourth quarter
in 2005, when the Company benefited from the impact of a new product launch as
well as revenues from a new multiple product contract.
EBITDA before repositioning expenses from the global PDS operations was
$6.3 million, being $1.5 million lower than the same period in 2005. The
decline reflects reduced volumes in the Canadian and Puerto Rico operations
and lower profitability from the Canadian operations as a result of the
strengthening Canadian dollar.
Corporate costs in the fourth quarter of 2006 were $0.5 million lower
than the same period last year.
Depreciation and Amortization Expense
Depreciation and amortization expense was $9.9 million in the fourth
quarter of 2006, compared with $7.8 million in the fourth quarter of 2005, an
increase of $2.1 million, or 27%. The depreciation and amortization charge in
2005 included a credit adjustment of $1.4 million in connection with the
finalization of the MOVA acquisition opening balance sheet. The remaining
increase principally reflects higher charges from the European operations.
Amortization of Intangible Assets
Amortization of intangible assets was $2.2 million in the fourth quarter
of 2006, compared with $3.4 million for the fourth quarter of 2005. The
amortization of intangible assets reflects the amortization of the remaining
balance of intangible assets in the Puerto Rico operations.
Interest Expense
Interest expense for the fourth quarter of 2006 was $6.2 million, up from
the $4.7 million charge in the fourth quarter of 2005. The increase reflects
higher debt levels along with increased borrowing costs as a result of the
amendments to the Company's North American loan facilities.
Amortization of Deferred Financing Costs
Amortization of deferred financing costs in the fourth quarter of 2006
was $0.3 million, compared with $1.3 million in the fourth quarter of 2005.
The charges in both years relate principally to the amortization of costs
associated with the North American credit facilities. The Company consolidated
its North American borrowing requirements in new credit facilities that were
completed during the first quarter of 2006. All unamortized costs associated
with the old facilities were charged to earnings at the time the new facility
was put in place.
Gain on Sale of Land
In the fourth quarter of 2005 the Company's French subsidiary recorded a
pre-tax gain of $4.6 million in connection with the sale of a parcel of land
adjacent to its principal operations which were not considered to be integral
to the long-term operations or expansion plans of the site. No amounts were
recorded in the fourth quarter of 2006.
Earnings (Loss) Before Income Taxes
The Company reported a loss before income taxes of $12.9 million,
compared with earnings before income taxes of $13.6 million in the same period
a year ago.
Income Taxes
The Company recorded an income tax charge of $9.5 million compared with a
charge of $5.2 million in the same period last year. The income tax charge in
the fourth quarter of 2006 includes a valuation reserve of $6.4 million
against future tax asset balances in the Canadian operations. In addition,
operating losses arising in Canada during the fourth quarter of 2006 were not
tax affected. The income tax charge was further impacted by operating losses
in the low tax jurisdiction of Puerto Rico and higher tax rates than in the
same period last year in Italy.
Net Earnings (Loss) and Earnings (Loss) Per Share
The Company recorded a net loss in the fourth quarter of 2006 of
$22.4 million, compared with net earnings of $8.4 million in the same period
last year. The loss per share was 24.1 cents, compared with earnings per share
of 9.3 cents a year earlier. The net loss in the fourth quarter of 2006
included a charge for repositioning expenses of $13.8 million which had the
impact of reducing net earnings by $12.2 million, or 13.2 cents per share. Net
earnings in the fourth quarter of 2005 included a gain on the sale of land in
France of $4.6 million which had the impact of increasing net earnings by
$3.0 million, or 3.5 cents per share.
The diluted loss per share in the fourth quarter of 2006 was 24.1 cents
compared with diluted earnings per share of 9.3 cents in the fourth quarter of
2005. Dilution arises solely from options issued under the Company's stock
option plan.
Twelve Months Ended October 31, 2006 Compared with Twelve Months Ended
October 31, 2005
The results for the twelve-month period ended October 31, 2006 include
the operations of MOVA for a full four quarters, while the results of the
comparative period include the operations of MOVA from the date of acquisition
on December 23, 2004 until October 31, 2005.
Revenues
Consolidated revenues for the twelve-month period ended October 31, 2006
increased 2% or $13.8 million to $712.2 million from $698.3 million in the
same period in 2005. Rx manufacturing and PDS revenues grew by 2% and 9%
respectively, while OTC manufacturing revenues declined by 4%.
Revenues from the Puerto Rico operations were $129.8 million,
$19.4 million lower than 2005. The 2006 results include a full first quarter
of operations compared with only five weeks of operations in 2005. The 2006
year-to-date decline in revenues in Puerto Rico principally reflect the loss
of revenues from a generic product where the Company's client lost a major
customer, other declines in base business volumes in Caguas and Manati, offset
in part by an additional seven weeks of operating activities in 2006.
Excluding the Puerto Rico operations, revenue growth from the Company's
other sites was $33.2 million, or 6%, in the twelve-month period ended
October 31, 2006. Of this increase, $19.2 million was derived from the
European operations, principally attributable to Rx manufacturing services,
which were up $12.3 million, or 7%, and PDS revenues, which were up
$5.0 million, or 28%, compared with the same period a year ago. North American
revenues grew $14.0 million, or 4%, compared with the same period a year ago,
principally attributable to an increase in Rx manufacturing revenues of
$19.0 million, or 11%, offset by a reduction in OTC revenues of $6.1 million,
or 6%.
Prescription manufacturing and development services, collectively
represented 85% of revenues, being 1% higher than the same period last year.
Geographically, North American revenues were $5.3 million or 1% lower
than the same period in the prior year. The decrease reflects a net decline in
revenue from the Puerto Rico operations and OTC business at Niagara/Burlington
and Cincinnati, offset in part by significant increases in volumes at Whitby
and at the Toronto Region Operations.
In Europe, revenues in 2006 were $19.2 million, or 9% higher than 2005.
The increase principally reflects higher Rx manufacturing and PDS revenues
from the Italian and UK operations. European currencies weakened against the
U.S. dollar in 2006 compared with the prior year. The Euro weakened
approximately 3% and the British pound sterling weakened approximately 2%
against the U.S. dollar, reducing reported revenues by approximately
$5.5 million. Had European currencies remained constant to the rates of the
prior year, European revenues would have been 12% higher than the same period
in 2005.
Operating Expenses
Operating expenses comprise processing costs (principally materials,
employee and other site-related costs), marketing, sales, service, corporate
support and administrative expenses. In the twelve-month period ended
October 31, 2006 operating expenses were $638.4 million, compared with
$600.4 million in the same period a year ago, an increase of 6%. The increase
principally reflects an additional seven weeks of operations in Puerto Rico,
the higher revenue base in the other operations, annual payroll-related
increases, additional GMP-related costs in the first half of the year in
Carolina in connection with the FDA warning letter and the impact of the
strengthening Canadian dollar relative to the U.S. dollar. These increases
were offset in part by lower bonus costs, savings from performance enhancement
plan and from weakening European currencies relative to the U.S. dollar.
Operating expenses as a percentage of revenues were 89.6%, compared with
86.0% in the prior year. Excluding the impact of the Puerto Rico operations,
operating expenses as a percentage of revenue were 87.4%, unchanged from the
same period a year ago. Operating expenses as a percentage of revenues for the
Puerto Rico operations were 98.9% compared with 80.3% in the same period a
year ago.
EBITDA before repositioning expenses and EBITDA margin before
repositioning expenses
On a consolidated basis for the year ended October 31, 2006, EBITDA
before repositioning expenses, representing earnings before repositioning
expenses, asset impairment charges, depreciation and amortization, gain on
sale of land, interest, debt prepayment charges, write-off of deferred
financing costs, and income taxes was $73.8 million, a decline of
$24.2 million, or 25%, from the comparable period in 2005. EBITDA margin
before repositioning expenses was 10.4% in the twelve months ended October 31,
2006, compared with 14.0% in the same period a year ago.
On a year-to-date basis the Canadian dollar has strengthened by
approximately 7% relative to the U.S. dollar, compared with the same period
last year. The Company estimates that, had the exchange rate remained the same
as last year, its EBITDA before repositioning expenses, net of hedging
activities, would have been approximately $5.2 million higher than was
reported.
EBITDA before repositioning expenses from the Puerto Rico commercial
operations was $0.7 million, compared with a $27.4 million in the same period
last year. This reflects declines in base business volumes in Caguas and
Manati and the impact in Carolina of the FDA Warning letter during the first
half of 2006, which resulted in additional costs and manufacturing
inefficiencies.
EBITDA before repositioning expenses from the Cincinnati commercial
operations was $13.3 million, being $1.9 million lower than the same period
last year. The decline principally reflects the impact of lower OTC volumes.
The Canadian commercial operations reported EBITDA before repositioning
expenses of $25.3 million, or $6.4 million higher than the same period last
year as improvements in the Toronto Region and Whitby operations were
partially offset by declining profitability in the OTC sites and from the
impact of the strengthening Canadian dollar.
In Europe, EBITDA before repositioning expenses from commercial
operations was $26.8 million being $1.0 million higher than the same period
last year. The improvement reflects increased capacity utilization at the
Italian and Swindon, U.K. facilities, offset in part by higher costs in
Bourgoin-Jallieu, France in connection with the transfer in of new business.
EBITDA before repositioning expenses from PDS operations was
$20.2 million, being $2.6 million lower than 2005. Improvements in
profitability in Cincinnati and Europe were offset by lower profitability in
the Canadian operations, as a result of lower revenues and from the continuing
strength in the Canadian dollar.
Corporate costs for the twelve months ended October 31, 2006 were
$0.4 million higher than the same period last year.
Asset Impairment Charge
During the third quarter of 2006 the Company determined that the carrying
value of MOVA's intangible assets, tangible capital assets (collectively the
"long-lived depreciable assets") and goodwill were impaired as a result of
certain events which occurred during the third quarter of 2006. These events
included: continued deterioration in revenues culminating in a significant
increase in losses reported by MOVA in the third quarter; suspension of
production of a major product due to concerns over product shelf life; the
risk of a decline in revenue of another major product as a result of the
approval by the U.S. Food and Drug Administration of a generic version of the
product; and the completion of a long range plan that showed a significant
reduction in earnings relative to prior forecasts.
The Company tested the recoverability of MOVA's long lived depreciable
assets and determined that expected future cash flows over the economic life
of the principal assets was less than the carrying value of the long-lived
depreciable assets. As a result the Company recorded an impairment charge of
$81.4 million. Based on preliminary analysis, the impairment charge as at
July 31, 2006 was allocated as to $66.2 million for intangible assets and
$15.2 million for tangible capital assets. Upon finalization of the analysis
the impairment charge for long lived and depreciable assets has been
re-allocated as to $51.9 million for intangible assets and $29.5 million for
tangible capital assets. The fair value of the intangible assets was
determined using a discounted cash flow methodology and the fair value of
tangible capital assets was based on a value in continued use, taking into
account utilization levels.
During the third quarter of 2006 the Company also tested the
recoverability of the goodwill associated with MOVA using a discounted cash
flow methodology, and recorded an impairment charge of $172.5 million,
representing the full value of the MOVA goodwill.
During the third quarter of 2006, the Company, as part of its ongoing
review of long term investments, concluded that its investment in the shares
of a drug technology company which is accounted for on the cost basis had an
other than temporary decline and wrote down its value by $0.8 million to its
market value as of July 31, 2006.
Depreciation and Amortization Expense
Depreciation and amortization expense was $39.9 million for the twelve
months ended October 31, 2006, compared with $33.4 million in the same period
of 2005, an increase of $6.5 million, or 20%. Of the increase, $2.5 million is
attributable to additional amounts relating to depreciation of the MOVA
assets. The remaining increase is principally attributable to completion of
capital programs, in particular at the Italian sites. Depreciation and
amortization expense includes the amortization of deferred pre-operating
costs.
Amortization of Intangible Assets
The amortization of intangible assets was $11.9 million in the twelve
months ended October 31 2006, compared with $11.2 million in the same period
of 2005. The amortization of intangible assets relates to the Puerto Rico
operations. The increase was due to the inclusion of a full quarter of
amortization in the first quarter of 2006, compared with five weeks in the
first quarter of 2005, offset by lower amortization charges in the fourth
quarter of 2006, as a result of the impairment charge made at the end of the
third quarter of 2006.
Interest Expense
Interest expense for the twelve-months ended October 31, 2006 was
$21.3 million, compared with $16.4 million in the same period a year ago. The
increase of $4.9 million, or 30%, compared with the prior year, reflects
higher debt levels and increased borrowing costs in the fourth quarter of 2006
as a result of the amendments to the Company's North American loan facilities
and the inclusion of a full quarter of interest expense in the first quarter
of 2006 related to the additional debt associated with the MOVA acquisition,
compared with five weeks in the first quarter of 2005.
Debt Prepayment Charges and Write-off of Deferred Financing Costs
During the first quarter of 2006, the Company incurred charges of
$1.6 million in connection with the cancellation and prepayment of certain of
its North American credit facilities. The Company also wrote off $6.3 million
in related deferred financing costs.
During the first quarter of 2005, the Company wrote off deferred
financing costs of $2.0 million associated with commitment fees paid for
financing that was not required in connection with the MOVA acquisition.
Amortization of Deferred Financing Costs
Amortization of deferred financing costs in the twelve months ended
October 31, 2006 was $0.9 million, compared with $4.8 million in the same
period of 2005. The decrease reflects lower amortization charges associated
with the Company's new North American financing facilities that were completed
on December 15, 2005.
Earnings (Loss) Before Income Taxes
The Company reported a loss before income taxes of $276.7 million in the
twelve months ended October 31, 2006, compared with earnings before income
taxes of $34.7 million in the same period a year ago.
Income Taxes
The income tax expense for the twelve months ended October 31, 2006 was
$11.5 million. The income tax charge in the twelve months ended October 31,
2006 includes a recovery of $2.6 million associated with the asset impairment
charge and an expense of $6.4 million in connection with Canadian valuation
reserve. Excluding the impact of the asset impairment charge and the valuation
reserve, the tax expense was $3.8 million, despite a loss before taxes of
$21.2 million. This compares with a tax charge of $13.1 million and an
effective tax rate of 37.7% for the same period a year ago. The charge from
operations in 2006 includes pre-tax losses from Puerto Rico, where the
effective tax rate averaged 1% and losses in Canada in the fourth quarter that
were not tax affected. In addition, income tax rates were higher in Italy than
the same period last year.
Net Earnings (Loss) and Earnings (Loss) Per Share
The Company recorded a net loss for the twelve months ended October 31,
2006 of $288.2 million, compared with net earnings of $21.6 million in the
same period a year ago. The loss per share was $3.10 compared with earnings
per share of 24.9 cents a year earlier. The net loss for the twelve months
ended October 31, 2006 included after tax repositioning expenses of
$12.2 million or 13.2 cents per share, after tax asset impairment charges of
$252.1 million, or 271.5 cents per share and after-tax costs for debt
prepayment charges and the write-off of deferred financing costs of
$6.2 million, or 6.6 cents per share. The net earnings for the twelve months
ended October 31, 2005 included an after tax gain on the sale of land in
France of $3.0 million, or 3.5 cents and after tax costs for the write-off of
deferred financing costs of $1.3 million, or 1.9 cents per share.
The diluted loss per share for the twelve months ended October 31, 2006
was $3.10 compared with diluted earnings per share of 24.8 cents in the same
period last year. Dilution arises solely from options issued under the
Company's stock option plan.
The average number of shares outstanding during the twelve-month period
ended October 31, 2006, determined on a basic and diluted bases, was higher by
7.0% and 6.5%, respectively, than for the same period last year. The increase
is the result of shares issued in the first quarter of 2005 in connection with
the MOVA acquisition.
Seasonal Variability of Results
Typically, the Company's manufacturing and PDS revenues are lower in the
first fiscal quarter. While this pattern was observed in 2006, in the first
quarter of 2005 the Company experienced relatively high revenues in its North
American commercial and PDS operations and in European PDS.
Liquidity and Capital Resources
Summary of Cash Flows
The following table summarizes the Company's cash flows for the periods
indicated:
Three months ended Twelve months ended
October 31, October 31,
2006 2005 2006 2005
---------------------- ----------------------
$ $ $ $
---------------------- ----------------------
Net earnings (loss) (22,416) 8,379 (288,150) 21,621
Asset impairment charge - - 254,661 -
Depreciation and
amortization 12,472 12,552 52,693 49,363
Write-off of deferred
financing costs - - 6,332 2,010
Employee future benefits 434 244 1,564 1,639
Future income taxes (3,514) 1,971 (6,235) 2,642
Gain on sale of land - (4,587) - (4,587)
Amortization of deferred
revenues (485) (280) (1,978) (898)
Other 154 371 1,587 1,745
Working capital 36,697 5,674 22,142 (4,640)
Increase in deferred
revenues - - 9,614 8,271
---------- ---------- ---------- ----------
Cash provided by operating
activities 23,342 24,324 52,230 77,166
Cash provided by (used in)
financing activities 32,566 (8,137) 44,460 211,144
Cash used in investing
activities (26,029) (10,523) (69,752) (266,476)
Other 847 494 1,278 (6,953)
---------- ---------- ---------- ----------
Net increase in cash and
cash equivalents 30,726 6,158 28,216 14,881
---------- ---------- ---------- ----------
---------- ---------- ---------- ----------
Cash Provided by Operating Activities
Cash provided by operating activities was $23.3 million in the fourth
quarter of 2006 compared with $24.3 million for the comparable period in 2005.
On a year-to-date basis, cash provided by operating activities was
$52.2 million, compared with $77.2 million in the same period last year. The
year-to-date decrease reflects lower earnings before non-cash charges offset
by cash flows arising from a reduction in non-cash working capital. The
reduction in non-cash working capital includes $9.5 million in amounts still
to be paid in connection with performance enhancement initiatives included in
repositioning expenses.
During the first quarter of 2006 and the third quarter of 2005 the
Company received $9.6 million and $8.3 million, respectively, from a client
for the reimbursement of costs the Company is incurring in connection with the
sterile cephalosporin lyophilization capacity being installed in Swindon, U.K.
This amount is recorded as an increase in deferred revenues and will be
recognized as income over the life of the commercial manufacturing contract.
Cash Used in Investing Activities
Cash used in investing activities in the fourth quarter of 2006 was
$26.0 million, compared with $10.5 million in the same period a year ago. The
increase is principally attributable to capital expenditures in connection
with the construction of a new 65,000 square foot facility in Swindon, U.K.
that will be dedicated to the manufacture of a new lyophilized cephalosporin
product for an established client.
Cash used in investing activities for the twelve months ended October 31,
2006 was $69.8 million, compared with $266.5 million in the same period of
2005. The 2005 amount included cash used in connection with the acquisition of
MOVA of $211.2 million.
On a year-to-date basis, additions to capital assets in 2006 were
$67.5 million, compared with $56.8 million in 2005. The major capital project
in 2006 relates to the Swindon expansion noted above. Total spending on this
project in 2006 was $28.8 million. The project is planned to be completed in
2007.
A summary of cash used in investing activities is as follows:
Three months ended Twelve months ended
October 31, October 31,
2006 2005 2006 2005
---------------------- ----------------------
$ $ $ $
---------------------- ----------------------
Acquisition net of cash
acquired - 3,343 - (211,178)
Additions to capital assets
- sustaining (7,555) (6,734) (17,804) (16,062)
- project-related (17,800) (11,177) (49,695) (40,730)
Proceeds on sale of land - 4,748 - 4,748
Increase in investments (49) - (49) -
Increase in deferred
pre-operating costs (625) (703) (2,204) (3,254)
---------- ---------- ---------- ----------
Cash used in investing
activities (26,029) (10,523) (69,752) (266,476)
---------- ---------- ---------- ----------
---------- ---------- ---------- ----------
Cash Provided by (Used in) Financing Activities
The principal financing activity for the twelve months ended October 31,
2006 was the completion in the first quarter of new credit facilities in North
America in the aggregate amount of $290.0 million to refinance existing debt
of the Company and its U.S. subsidiaries. The Company was able to release
$7.8 million of restricted cash that had previously been held as security for
certain of the cancelled facilities. The Company also incurred costs in
connection with the refinancing of $2.6 million.
During the first quarter of 2006 the Company's Italian subsidiary also
entered into a new long-term debt facility in the amount of 28.5 million euros
($33.9 million) to replace existing loans.
A summary of cash provided by (used in) financing activities is as
follows:
Three months ended Twelve months ended
October 31, October 31,
2006 2005 2006 2005
---------------------- ----------------------
$ $ $ $
---------------------- ----------------------
Decrease in bank
indebtedness 3,041 1,536 (11,096) (6,195)
Increase in long-term debt 42,443 46,355 416,389 341,445
Repayment of long-term debt (11,790) (55,667) (364,800) (304,838)
Decrease (increase) in
restricted cash - (364) 7,805 (116)
Decrease (increase) in
deferred financing costs (1,175) 3 (3,965) (9,446)
Proceeds on issue of common
shares before costs 47 - 127 199,241
Share issue costs - - - (8,947)
---------- ---------- ---------- ----------
Cash provided by (used in)
financing activities 32,566 (8,137) 44,460 211,144
---------- ---------- ---------- ----------
---------- ---------- ---------- ----------
Financing Arrangements and Ratios
At October 31, 2006, the Company's consolidated ratio of interest-bearing
debt to shareholders' equity was 139.4%, compared with 56.1% at October 31,
2005. The significant increase reflects an increase in interest-bearing debt
combined with a $289.1 million reduction in shareholders' equity, arising
principally from the asset impairment charge in the third quarter of 2006.
On December 15, 2005, the Company completed the negotiation of new credit
facilities in North America in the aggregate amount of $290.0 million to
refinance existing debt of the Company and its U.S. subsidiaries, including
its subsidiaries in Puerto Rico. The new facilities replaced: (i) existing
credit facilities that were available to the Company's North American
operations, including those that were established at the time of acquisition
of MOVA in December 2004; and (ii) debt of MOVA that was assumed at the time
of acquisition by the Company. The new credit facilities comprise two term
loans in the aggregate amount of $215.0 million and three-year revolving
facilities in the aggregate totaling $75.0 million. The term loans consist of
a five-year term loan of $50.0 million and six-year term loan of
$165.0 million. The new facilities are secured by the North American assets of
Patheon and its subsidiaries, including those in Puerto Rico.
During the third quarter of 2006, certain of the financial covenant tests
included in the North American loan facilities were amended to ensure that the
Company remained in compliance as at July 31, 2006. During the fourth quarter
of 2006, the Company entered into a further agreement with its lenders to
amend the North American loan facilities. The agreement reduced the amount of
the revolving credit facilities from $75,000,000 to $60,000,000 and
established amended financial covenants, including trailing 12-month
debt-to-EBITDA covenants. The amended covenants cover a six-month period
ending on March 31, 2007.
If the Company is not able to implement a long term improvement in its
capital structure as a result of its review of strategic and financial
alternatives, it anticipates that it will be in default of the covenants under
the North American loan facilities as at April 30, 2007 and the lenders could
demand repayment of all amounts outstanding under these credit facilities. As
at November 30, 2006, $237.9 million was outstanding under these facilities
($246.0 million as at October 31, 2006). In addition, any such default would
constitute a default under a lending facility of the company's U.K.
subsidiary, allowing the lender under this facility to demand repayment of all
amounts outstanding under that facility. As at November, 2006, $24.6 million
was outstanding under that facility ($23.9 million as a October 31, 2006).
In accordance with Emerging Issues Committee Abstract 59, the Company has
re-classified $263.8 million of debt from long-term debt to current
indebtedness. This amount represents the long-term portion of the Company's
indebtedness under its North American loan facilities ($239.9 million) and the
indebtedness of the Company's U.K. subsidiary under its credit facility
($23.9 million), which was previously classified as long-term debt. Emerging
Issues Committee Abstract-59 requires this reclassification, in light of the
North American loan facilities amendments to prevent a default, unless a
violation of the covenants under these credit facilities at a determination
date within one year of the balance sheet date is not likely.
On December 22, 2005, the Company's Italian subsidiary entered into a new
long-term debt facility. The new loan replaced four separate term loans it had
with an Italian bank. The new loan in the amount of 28.5 million euros
($33.9 million) is collateralized by a mortgage over land and buildings.
Adequacy of Financial Resources
As at October 31, 2006 the Company has a working capital deficiency of
$175.8 million due to the reclassification of long-term debt to short term
debt as noted above. The Company is able to borrow under its $60 million North
American revolving loan facility, and as at October 31, 2006, $36.9 million
was borrowed under this facility ($35.3 million as at November 30, 2006). In
addition as at October 31, 2006 the Company had consolidated cash reserves of
$50.7 million (approximately $45.1 million as at November 30, 2006). The
Company's ability to fund its normal operating activities and debt service
requirements is dependent on it being able to improve its long-term capital
structure as a result of its review of strategic and financial alternatives.
Critical Accounting Policies and Estimates
Going Concern Uncertainty
These financial statements have been prepared on a going concern basis,
which contemplates the realization of assets and the discharge of liabilities
in the normal course of business for the foreseeable future. As at October 31,
2006, the Company had a working capital deficiency of $175.8 million as a
result of the reclassification of $263.8 million of debt from long term to
short term, as discussed under "Liquidity and Capital Resources - Financing
Arrangements and Ratios" above. The Company's ability to continue as a going
concern is uncertain and is dependent upon the successful outcome of the
review, announced on September 11, 2006, of strategic and financial
alternatives. If the Company is not able to implement a long term improvement
in its capital structure as a result of this review, it anticipates that it
will be in default of the covenants under the North American loan facilities
as at April 30, 2007.
These financial statements do not give effect to any adjustments which
would be necessary should the Company be unable to continue as a going concern
and, therefore, be required to realize its assets and discharge its
liabilities in other than the normal course of business and at amounts
different from those reflected in the accompanying financial statements.
General
Patheon's significant accounting policies are described in Note 1 to the
2005 audited consolidated financial statements. The most critical of these
policies are those related to revenue recognition, deferred revenues,
intangible assets, goodwill, employee future benefits, and income taxes,
(Notes 1, 6, 8, 12 and 16 of the 2005 audited consolidated financial
statements).
The preparation of the consolidated financial statements in conformity
with Canadian generally accepted accounting principles requires management to
make estimates and assumptions that affect: the reported amounts of assets and
liabilities; the disclosure of contingent assets and liabilities at the date
of the consolidated financial statements; and the reported amounts of revenue
and expenses in the reporting period. Management believes that the estimates
and assumptions used in preparing its consolidated financial statements are
reasonable and prudent; however, actual results could differ from those
estimates.
The Company's Accounting Policies have been reviewed and discussed with
the Company's Audit Committee.
Revenue Recognition
The Company recognizes revenue for its commercial manufacturing and
pharmaceutical development services when services are completed in accordance
with specific agreements with its clients and when all costs connected with
providing these services have been incurred, the price is fixed or
determinable and collectibility is reasonably assured. Client deposits on
pharmaceutical development services in progress are included in accounts
payable and accrued liabilities.
The Company does not receive any fees on signing of contracts. In the
case of pharmaceutical development services, revenue is recognized on the
achievement of specific milestones. In the case of commercial manufacturing
services, revenue is recognized when services are complete and the product has
met rigorous quality assurance testing.
Deferred Revenues
The costs of certain capital assets are reimbursed to the Company by the
pharmaceutical companies that are to benefit from the improvements in
connection with the manufacturing and packaging agreements in force. These
reimbursements are recorded as deferred revenues and are recognized as income
over the remaining minimum term of the agreements. During the fourth quarter
of 2006, $0.5 million was recognized as earnings. During the twelve months
ended October 31, 2006, $2.0 million was recognized as earnings.
Intangible Assets
Intangible assets represent the values assigned to acquired client
contracts and relationships. They are amortized on a straight-line basis over
their estimated economic life. During the fourth quarter of 2006, $2.2 million
was charged to earnings. During the twelve months ended October 31, 2006,
$11.9 million was charged to earnings.
On an ongoing basis, the Company reviews whether there are any indicators
of impairment. If such indicators are present, the Company assesses the
recoverability of intangible assets by determining whether the carrying value
of such assets can be recovered through undiscounted future cash flows. If the
sum of undiscounted future cash flows is less than the carrying amount, the
excess of the carrying amount over the estimated fair value, based on
discounted future cash flows, is recorded as a charge to net earnings. In the
third quarter of 2006, the Company recorded an impairment charge of
$51.9 million. The Company has re-evaluated the economic life of the
intangible assets and is amortizing the remaining balance on a straight line
basis over a period of five years.
Valuation of Goodwill
The Company evaluates goodwill for impairment at least annually and
reviews if there are any indicators of impairment on an ongoing basis. If the
carrying value of the reporting unit exceeds the reporting unit's fair value,
any excess represents an impairment loss. In the third quarter of 2006, the
Company recorded an impairment charge of $172.5 million to reduce the carrying
value of the MOVA goodwill to zero.
The goodwill shown on the financial statements for the period ended
October 31, 2006 was $3.1 million and relates to the acquisition in 2000 of
the remaining shares of Global Pharm Inc., which now operates as Toronto York
Mills Operations.
Income Taxes
In accordance with Canadian GAAP, the Company uses the liability method
of accounting for future income taxes and provides for future income taxes for
significant temporary timing differences.
Preparation of the consolidated financial statements requires an estimate
of income taxes in each of the jurisdictions in which the Company operates.
The process involves an estimate of the Company's current tax exposure and an
assessment of temporary differences resulting from differing treatment of
items such as depreciation and amortization for tax and accounting purposes.
These differences result in future tax assets and liabilities and are
reflected in the consolidated balance sheet.
Future tax assets of $21.8 million have been recorded at October 31,
2006. The future tax assets are primarily composed of accounting provisions
related to pension and post-retirement benefits not currently deductible for
tax purposes, the tax benefit of net operating loss carry forwards related to
the U.K. and share issue costs in relation to the acquisition of MOVA. The
Company evaluates quarterly the ability to realize its future tax assets. The
factors used to assess the likelihood of realization are the Company's
forecast of future taxable income and available tax planning strategies that
could be implemented to realize the future tax assets. In the fourth quarter
of 2006 the Company recorded a valuation reserve of $6.4 million against
future tax assets in its Canadian operations, as latest financial forecasts,
combined with potential tax planning strategies did not support the likely
realization of the related future tax assets.
Future tax liabilities of $33.1 million have been recorded at October 31,
2006. This liability has arisen primarily on tax depreciation in excess of
book depreciation.
The Company's tax filings are subject to audit by taxation authorities.
Although management believes that it has adequately provided for income taxes
based on the information available, the outcome of audits cannot be known with
certainty and the potential impact on the financial statements is not
determinable.
Employee Future Benefits
The Company provides to retired employees pensions and post-employment
benefits, including medical benefits and dental care. The determination of the
obligation and expense for defined benefit pensions and post-employment
benefits is dependent on the selection of certain assumptions used by
actuaries in calculating such amounts. Those assumptions are disclosed in Note
12 to the Company's 2005 audited consolidated financial statements.
Variable Interest Entities
The Company has adopted Accounting Guideline 15 "Consolidation of
Variable Interest Entities". The Guideline requires consolidation of entities
that are deemed to be subject to control on a basis other than through
ownership of a voting interest in the entity. The Company has concluded that
it does not have any variable interest entities and there is no impact on the
consolidated financial statements as a result of adopting the Guideline.
Risk Management
The following are updates to certain of the risks and uncertainties
described in the Management's Discussion and Analysis section of Patheon's
2005 Annual Report, available on SEDAR (www.sedar.com) or on Patheon's website
(www.patheon.com).
Foreign Currency
The Company's business activities are conducted in several currencies -
Canadian dollars and U.S. dollars for the Canadian operations, U.S. dollars
for the U.S. operations and euros and U.K. sterling for the European
operations.
Since the European and U.S. operations conduct business principally in
their respective local currencies, the exposure to foreign currency gains and
losses is not significant. However, the Company's Canadian operations
negotiate sales contracts for payment in both U.S. and Canadian dollars, and
materials and equipment are purchased in both U.S. and Canadian dollars. The
majority of its non-material costs (including payroll, facilities' costs and
costs of locally sourced supplies and inventory) are denominated in Canadian
dollars. Approximately 60% to 70% of revenues of the Canadian operations and
approximately 10% to 20% of its operating expenses are transacted in U.S.
dollars. As a result, the Company may experience trading and translation gains
or losses because of volatility in the exchange rate between the Canadian
dollar and the U.S. dollar. Based on the Company's current U.S. denominated
net inflows, for each one-cent change in the Canadian-U.S. rate, the impact on
annual pretax earnings is approximately $1.1 million.
The Company mitigates its foreign exchange risk by engaging in foreign
currency hedging activities using derivative financial instruments. At
October 31, 2006 the Company had outstanding foreign exchange contracts to
sell US$60 million. The contracts mature at the latest on October 29, 2007 and
the mark-to-market value at October 31, 2006 was an unrealized loss of
$1.4 million. The Company does not purchase any derivative instruments for
speculative purposes.
Translation gains and losses related to the carrying value of the
Company's foreign operations and certain foreign denominated debt held by the
Company designated as a hedge against the carrying value of certain foreign
operations, are deferred and included in the cumulative translation account in
shareholders' equity. At October 31, 2006, the Company had designated
$200 million US dollar denominated debt as a hedge against its equity
investment in the U.S.A and Puerto Rico. The balance in the cumulative
translation adjustment account at October 31, 2006 was a $36.1 million gain
compared with a $38.1 million gain at October 31, 2005.
Interest Rate Exposure
The Company has exposure to movements in interest rates. During the
second quarter of 2006, the Company unwound the interest rate swap contracts
that were put in place during the first quarter of 2006 to convert
$107.5 million of debt drawn on the Company's new North American term
facilities from floating interest rates to fixed interest rates. The Company
realized a gain of $1.1 million on the unwinding of the swap. The gain is
being amortized as a credit to the interest expense over six years, reflecting
the term of the original swap contracts.
At October 31, 2006, 93% of the Company's total debt portfolio was
subject to movements in floating interest rates. Assuming no change to the
structure of the debt portfolio, a 1% change in floating interest rates has an
impact on annual pre-tax earnings of approximately $3.3 million.
The Company continues to monitor floating and long-term interest rates
and may enter into new arrangements in the future that reduce the Company's
exposure to changes in floating interest rates.
Additional Information
Share Capital
As of October 31, 2006, the Company had 92,950,688 common shares
outstanding.
Public Securities Filings
Other information about the Company, including the annual information
form and other disclosure documents, reports, statements or other information
that is filed with Canadian securities regulatory authorities can be accessed
through SEDAR at www.sedar.com.
Outlook
Revenues from the current operations for fiscal 2007 are expected to be
comparable to 2006, with decreases in revenues from manufacturing OTC products
in Canada offset by increases in revenues from pharmaceutical development
services and the manufacture of Rx products in the United States and Europe.
Revenues for the first quarter of 2007 are anticipated to be slightly
higher than the same period in fiscal 2006, but less than the fourth quarter
of 2006, due in part to seasonal variability of results.
Auditor Review
The accompanying unaudited financial statements of the Company have been
prepared by and are the responsibility of management. The Company's
independent auditor has not performed a review of the financial statements for
the three-month and twelve-month periods ended October 31, 2006, or the three
months ended October 31, 2005.
FORWARD-LOOKING STATEMENTS
This news release and MD&A contains forward-looking statements which
reflect management's expectations regarding the Company's future growth,
results of operations, performance (both operational and financial) and
business prospects and opportunities. Wherever possible, words such as
"plans," "expects" or "does not expect," "forecasts," "anticipates" or "does
not anticipate," "believes," "intends" and similar expressions or statements
that certain actions, events or results "may", "could", "would", "might" or
"will" be taken, occur or be achieved have been used to identify these
forward-looking statements. Although the forward-looking statements contained
in this news release and MD&A reflect management's current assumptions based
upon information currently available to management and based upon what
management believes to be reasonable assumptions, the Company cannot be
certain that actual results will be consistent with these forward-looking
statements. Forward-looking statements necessarily involve significant known
and unknown risks, assumptions and uncertainties that may cause the Company's
actual results, performance, prospects and opportunities in future periods to
differ materially from those expressed or implied by such forward-looking
statements. These risks and uncertainties include, among other things: the
market demand for client products; dependence on key clients; the ability to
identify and secure new contracts; regulatory matters, including compliance
with pharmaceutical regulations; management of expanded operations;
international operations risks; currency risks; competition; product liability
claims; integration of new operations; financing risks and interest rate
risks. Although the Company has attempted to identify important risks and
factors that could cause actual actions, events or results to differ
materially from those described in forward-looking statements, there may be
other factors and risks that cause actions, events or results not to be as
anticipated, estimated or intended. There can be no assurance that forward-
looking statements will prove to be accurate, as actual results and future
events could differ materially from those anticipated in such statements.
Accordingly, readers should not place undue reliance on forward-looking
statements. These forward-looking statements are made as of the date of this
news release and MD&A and, except as required by law, the Company assumes no
obligation to update or revise them to reflect new events or circumstances.